Furthermore, previous studies showed that bromodomain and extraterminal domain inhibitor (BETi) had potent antagonism to MYC transcriptional activity and protein expression and exhibited antitumor activity in various hematological malignancies, including DLBCL (68–70). The gene discussed is MYC; the disease is hematologic disorder.